Early access avacopan for ANCA vasculitis
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This study looks at how well the drug avacopan works for people with a rare blood vessel disease called ANCA-associated vasculitis. It aims to help patients who are starting this treatment by tracking real-world results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of vasculitis called GPA or MPA (blood vessel inflammation).
- You are about to start or have just started taking avacopan.
- You agree to let the researchers use your medical information for this study.
- You have active disease that can be measured with a medical test or exam.
- You are 16 years old or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with ANCA-associated vasculitis to better understand the treatment using AAV. Your participation would mainly involve agreeing to be in the study and meeting the study’s disease criteria.
This Phase 4 trial studies whether rituximab combined with telitacicept works better and is safe for people with severe active ANCA-associated vasculitis (including certain subtypes like GPA or MPA). If you meet specific blood test and disease activity criteria, you may be considered to help lower inflammation and prevent flare-ups.
This study looks at different types of blood vessel inflammation (vasculitis) to learn more about why they happen and how they progress. By joining, you may help doctors better understand these conditions and improve future treatments.
This trial tests a medication called avacopan for people with ANCA-associated vasculitis, a condition where the immune system attacks blood vessels. Avacopan is taken with standard treatments to help control the disease and may reduce the need for steroids.
This trial tests if adding avacopan, a medication that helps calm the immune system, to usual treatment can improve kidney function in people with a type of blood vessel inflammation called vasculitis that affects the kidneys. It's for people with severe kidney involvement who are starting standard treatment.
This study compares a new drug (avacopan) with lower doses of steroids to standard steroid treatment for people newly diagnosed with ANCA-associated vasculitis. The goal is to see if avacopan can control your disease with fewer steroid side effects.
Hear when a new ANCA Associated Vasculitis (AAV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.